Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21122578 | 0.87 | MEN1 (0.71) | MEN1KMT2AEPHX2CASP2RECQL | |
| SCHEMBL11396166 | 0.83 | CASP2 (0.59) | MEN1KMT2AEPHX2CASP2NAAA | |
| SCHEMBL18362143 | 0.82 | MEN1 (0.56) | MEN1KMT2ACASP2ATMRECQL | |
| SCHEMBL7531907 | 0.80 | MEN1 (0.38) | MEN1KMT2AEPHX2CASP2CYP2D6 | |
| SCHEMBL20942602 | 0.80 | MEN1 (0.54) | MEN1KMT2ARECQLALDH1A1 | |
| SCHEMBL12643925 | 0.79 | CASP2 (0.55) | EPHX2CASP2NAAA | |
| SCHEMBL23929057 | 0.79 | ACP1 (0.38) | MEN1KMT2AEPHX2CASP2CYP2D6 | |
| SCHEMBL4809608 | 0.79 | ALDH1A1 (0.36) | MEN1KMT2AEPHX2CASP2CYP2D6 | |
| SCHEMBL30407466 | 0.79 | L3MBTL1 (0.47) | MEN1KMT2ACASP2NAAACYP2D6 | |
| SCHEMBL4809620 | 0.79 | ALDH1A1 (0.36) | MEN1KMT2AEPHX2CASP2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034171-A1 | Composition for Improving Cognitive Function | PERRY STEPHEN C (US) | 2026-02-05 | — | — | US | claimed |
| CN-101268093-A | Age inhibitors | PHARMAMENS (FR) | 2008-09-17 | — | — | CN | claimed |
| US-20260034171-A1 | Composition for Improving Cognitive Function | PERRY STEPHEN C (US) | 2026-02-05 | — | — | US | disclosed |
| US-20220002317-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2022-01-06 | — | — | US | disclosed |
| WO-2021263039-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-3489309-A1 | 4,4-DISUBSTITUTED CYCLOHEXYL BRIDGED HEPTAMETHINE CYANINE DYES AND USES THEREOF | Visen Medical, Inc. (US) | 2019-05-29 | — | — | EP | disclosed |
| EP-3103797-B1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3103797-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20130123215-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| CN-101268093-B | Age inhibitors | PHARMAMENS | 2013-04-03 | — | — | CN | disclosed |
| CN-101268093-A | Age inhibitors | PHARMAMENS (FR) | 2008-09-17 | — | — | CN | disclosed |
| WO-2004004651-A2 | THERAPEUTIC AMIDES | WAYNE STATE UNIVERSITY (US) | 2004-01-15 | — | — | WO | disclosed |
| EP-0022022-A1 | Acylated derivatives of taurine and their salts, and process for their preparation | SOCIETE BFB (FR) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034171-A1 | Composition for Improving Cognitive Function | PHOSPHO1, PSEN1, S100B | MEN1 3089/4885KMT2A 1829/4885EPHX2 889/4885 |
| US-20130123215-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | FPR1, FPR2, FPR3 | MEN1 4449/4885KMT2A 4728/4885EPHX2 2230/4885 |
| US-20220002317-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAA1 | MEN1 3562/4885KMT2A 684/4885EPHX2 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.